Unravelling tissue pathology by multiplexed imaging
Related
Join Dr Leeat Keren as she describes multiplexed ion beam imaging by time of flight (MIBI-TOF) technology and provides expert tips on choosing appropriate antibodies for multiplexed imaging experiments
Understanding tissue structure and function is crucial for answering emerging questions in cancer, immunology, and neurobiology. To achieve this, methods and tools are required that can quantify the expression of multiple proteins while preserving spatial information.
MIBI-TOF, an instrument that uses bright ion sources and orthogonal time of flight mass spectrometry to image metal-tagged antibodies1, is emerging as a key method for visualising multiple proteins in situ.
In this webinar, Dr Leeat Keren reviews how to plan and use this technique in multiplexed imaging experiments, from choosing and validating antibodies through to data analysis.
About the presenter:
Dr Leeat Keren is the Fred and Andrea Fallek President’s Development Chair at the Weizmann Institute of Science in Israel. Her research focuses on the study of tumor-immune interactions using multiplexed imaging. She develops computational tools that allow the teasing of various layers of information from rich multiplexed-imaging data and employs them to infer design principles in tumor immunology.
Dr Keren completed her BSc at Tel-Aviv University and her MSc and PhD in computational biology at the Weizmann Institute of Science with Professor Eran Segal and Professor Ron Milo. In 2016, she joined the lab of Dr Michael Angelo in Stanford University as a Fulbright, EMBO, and Damon Runyon fellow, spearheading the development of MIBI-TOF, a platform for multiplexed imaging of tissues. In 2020, she returned to the Weizmann Institute of Science, joining the Department of Molecular Cell Biology.
Have questions about this webinar? Contact us at events@abcam.com
References:
1. Keren, L. et al. MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure Science Advances 5(10) (2019)